T Lymphocyte Activation Antigen CD80 - Pipeline Review, H2 2019
T Lymphocyte Activation Antigen CD80 - Pipeline Review, H2 2019
SUMMARY
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Cluster of differentiation 80 or CD80 or B7-1 is a protein found on dendritic cells, activated B cells and monocytes. The activated protein induces T-cell proliferation and cytokine production. T-cell proliferation and cytokine production is induced by the binding of CD28.
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 1, 4 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones, Hematological Disorders, Infectious Disease, Metabolic Disorders, Musculoskeletal Disorders, Ophthalmology, Respiratory and Undisclosed which include indications Rheumatoid Arthritis, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Cytopenia, Dermatomyositis, Focal Segmental Glomerulosclerosis (FSGS), Graft Versus Host Disease (GVHD), Granulomatosis with Polyangiitis (Wegener's Granulomatosis), Immunoglobulin G4-Related Disease (IgG4-RD), Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Juvenile Rheumatoid Arthritis, Kidney Transplant Rejection, Lupus Nephritis, Melanoma, Myasthenia Gravis, Nephrotic Syndrome, Non-Small Cell Lung Cancer, Polymyalgia Rheumatica (PMR), Polymyositis/Idiopathic Inflammatory Myopathy, Sicca Syndrome (Sjogren), Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Type 1 Diabetes (Juvenile Diabetes), Unspecified, Uveitis and Vitiligo.
The latest report T Lymphocyte Activation Antigen CD80 - Pipeline Review, H2 2019, outlays comprehensive information on the T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Cluster of differentiation 80 or CD80 or B7-1 is a protein found on dendritic cells, activated B cells and monocytes. The activated protein induces T-cell proliferation and cytokine production. T-cell proliferation and cytokine production is induced by the binding of CD28.
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 1, 4 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones, Hematological Disorders, Infectious Disease, Metabolic Disorders, Musculoskeletal Disorders, Ophthalmology, Respiratory and Undisclosed which include indications Rheumatoid Arthritis, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Cytopenia, Dermatomyositis, Focal Segmental Glomerulosclerosis (FSGS), Graft Versus Host Disease (GVHD), Granulomatosis with Polyangiitis (Wegener's Granulomatosis), Immunoglobulin G4-Related Disease (IgG4-RD), Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Juvenile Rheumatoid Arthritis, Kidney Transplant Rejection, Lupus Nephritis, Melanoma, Myasthenia Gravis, Nephrotic Syndrome, Non-Small Cell Lung Cancer, Polymyalgia Rheumatica (PMR), Polymyositis/Idiopathic Inflammatory Myopathy, Sicca Syndrome (Sjogren), Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Type 1 Diabetes (Juvenile Diabetes), Unspecified, Uveitis and Vitiligo.
The latest report T Lymphocyte Activation Antigen CD80 - Pipeline Review, H2 2019, outlays comprehensive information on the T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80)
- The report reviews T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics and enlists all their major and minor projects
- The report assesses T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Overview
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Companies Involved in Therapeutics Development
Adagene (Suzhou) Ltd
Alphamab Oncology
AstraZeneca Plc
BioAtla LLC
Bristol-Myers Squibb Co
Cue Biopharma Inc
GeneFrontier Corp
GI Innovation Co Ltd
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Drug Profiles
abatacept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADG-116 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BA-3071 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
belatacept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CUE-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GI-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-5265 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Inhibit CTLA-4 for Unspecified Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Cancer Testis Antigen, CD80 and CD40L for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target CD80 and IL-2 for Acute Myeloblastic Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Dormant Products
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Discontinued Products
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Product Development Milestones
Featured News & Press Releases
Dec 05, 2019: BMS’ Orencia gets breakthrough status in US to prevent GvHD
Nov 07, 2019: Bristol-Myers Squibb Underscores Precision-Focused Immunology Leadership with New Data on ORENCIA (abatacept) in Early RA, ACPA-Positive Patients Presented at 2019 ACR/ARP Annual Meeting
Jun 13, 2019: New mechanistic study explores the relationship between a key genetic marker and clinical efficacy of ORENCIA (abatacept) or adalimumab in moderate-to-severe early Rheumatoid Arthritis patients
Mar 11, 2019: BMSKK and ONO submit supplemental applications of Orencia for I.V. infusion, Orencia Syringe for S.C. Injection and Orencia Autoinjector for S.C. Injection, a selective T-cell co-stimulation modulator, for inhibition of structural damage of joints in Rheumatoid Arthritis
Feb 27, 2019: BioAtla presents CAB-CTLA-4 program BA3071 data at The American Association For Cancer Research Annual Meeting
Jan 31, 2019: CHMP recommended extension of indication for Orencia
Oct 17, 2018: Bristol-Myers Squibb to showcase immunoscience research and biomarker-guided treatment approaches at the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting
Jun 13, 2018: Bristol-Myers Squibb to Present New Research Findings on the Treatment of Patients with Early Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR 2018)
Feb 23, 2018: Orencia for Intravenous Infusion 250 mg, Selective T-cell Co-stimulation Modulator: Approval for Additional Indication of Active Polyarticular Juvenile Idiopathic Arthritis for Partial Change in Approved items of Manufacturing and Marketing Approval in Japan
Dec 09, 2017: Immunotherapy Drug for Rheumatoid Arthritis Nearly Eliminates Severe Acute Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplant
Nov 13, 2017: Bristol-Myers Squibb’s Orencia Rejects For Use Within NHS Scotland
Nov 02, 2017: Bristol-Myers Squibb to Showcase Company's Progress in Researching Personalized Medicine for the Potential Treatment of Autoimmune Diseases at 2017 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting
Jul 26, 2017: Bristol-Myers Squibb’s ORENCIA (abatacept) Receives Second European Commission Approval in Less than a Year - New Approval for Treatment of Active Psoriatic Arthritis
Jul 06, 2017: Bristol-Myers Squibb's ORENCIA (abatacept) Receives FDA Approval for Treatment of Active Psoriatic Arthritis in Adults
Jun 14, 2017: Bristol-Myers Squibb To Present New Research Related to the Treatment of Rheumatoid Arthritis Patients With Highly Active, Progressive Disease at the Annual European Congress of Rheumatology (EULAR 2017)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Overview
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Companies Involved in Therapeutics Development
Adagene (Suzhou) Ltd
Alphamab Oncology
AstraZeneca Plc
BioAtla LLC
Bristol-Myers Squibb Co
Cue Biopharma Inc
GeneFrontier Corp
GI Innovation Co Ltd
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Drug Profiles
abatacept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADG-116 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BA-3071 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
belatacept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CUE-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GI-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-5265 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Inhibit CTLA-4 for Unspecified Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Cancer Testis Antigen, CD80 and CD40L for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target CD80 and IL-2 for Acute Myeloblastic Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Dormant Products
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Discontinued Products
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Product Development Milestones
Featured News & Press Releases
Dec 05, 2019: BMS’ Orencia gets breakthrough status in US to prevent GvHD
Nov 07, 2019: Bristol-Myers Squibb Underscores Precision-Focused Immunology Leadership with New Data on ORENCIA (abatacept) in Early RA, ACPA-Positive Patients Presented at 2019 ACR/ARP Annual Meeting
Jun 13, 2019: New mechanistic study explores the relationship between a key genetic marker and clinical efficacy of ORENCIA (abatacept) or adalimumab in moderate-to-severe early Rheumatoid Arthritis patients
Mar 11, 2019: BMSKK and ONO submit supplemental applications of Orencia for I.V. infusion, Orencia Syringe for S.C. Injection and Orencia Autoinjector for S.C. Injection, a selective T-cell co-stimulation modulator, for inhibition of structural damage of joints in Rheumatoid Arthritis
Feb 27, 2019: BioAtla presents CAB-CTLA-4 program BA3071 data at The American Association For Cancer Research Annual Meeting
Jan 31, 2019: CHMP recommended extension of indication for Orencia
Oct 17, 2018: Bristol-Myers Squibb to showcase immunoscience research and biomarker-guided treatment approaches at the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting
Jun 13, 2018: Bristol-Myers Squibb to Present New Research Findings on the Treatment of Patients with Early Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR 2018)
Feb 23, 2018: Orencia for Intravenous Infusion 250 mg, Selective T-cell Co-stimulation Modulator: Approval for Additional Indication of Active Polyarticular Juvenile Idiopathic Arthritis for Partial Change in Approved items of Manufacturing and Marketing Approval in Japan
Dec 09, 2017: Immunotherapy Drug for Rheumatoid Arthritis Nearly Eliminates Severe Acute Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplant
Nov 13, 2017: Bristol-Myers Squibb’s Orencia Rejects For Use Within NHS Scotland
Nov 02, 2017: Bristol-Myers Squibb to Showcase Company's Progress in Researching Personalized Medicine for the Potential Treatment of Autoimmune Diseases at 2017 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting
Jul 26, 2017: Bristol-Myers Squibb’s ORENCIA (abatacept) Receives Second European Commission Approval in Less than a Year - New Approval for Treatment of Active Psoriatic Arthritis
Jul 06, 2017: Bristol-Myers Squibb's ORENCIA (abatacept) Receives FDA Approval for Treatment of Active Psoriatic Arthritis in Adults
Jun 14, 2017: Bristol-Myers Squibb To Present New Research Related to the Treatment of Rheumatoid Arthritis Patients With Highly Active, Progressive Disease at the Annual European Congress of Rheumatology (EULAR 2017)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Adagene (Suzhou) Ltd, H2 2019
Pipeline by Alphamab Oncology, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by BioAtla LLC, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Cue Biopharma Inc, H2 2019
Pipeline by GeneFrontier Corp, H2 2019
Pipeline by GI Innovation Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Adagene (Suzhou) Ltd, H2 2019
Pipeline by Alphamab Oncology, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by BioAtla LLC, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Cue Biopharma Inc, H2 2019
Pipeline by GeneFrontier Corp, H2 2019
Pipeline by GI Innovation Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
COMPANIES MENTIONED
Adagene (Suzhou) Ltd
Alphamab Oncology
AstraZeneca Plc
BioAtla LLC
Bristol-Myers Squibb Co
Cue Biopharma Inc
GeneFrontier Corp
GI Innovation Co Ltd
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
COMPANIES MENTIONED
Adagene (Suzhou) Ltd
Alphamab Oncology
AstraZeneca Plc
BioAtla LLC
Bristol-Myers Squibb Co
Cue Biopharma Inc
GeneFrontier Corp
GI Innovation Co Ltd
